- Home
- CARM
as 12-18-2024 12:33pm EST
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 35.5M | IPO Year: | N/A |
| Target Price: | $4.57 | AVG Volume (30 days): | 329.1K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.38 - $3.16 | Next Earning Date: | 11-07-2024 |
| Revenue: | $20,268,000 | Revenue Growth: | 41.13% |
| Revenue Growth (this year): | 46.34% | Revenue Growth (next year): | -5.06% |
Latest Carisma Therapeutics Inc. News
CARM Breaking Stock News: Dive into CARM Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
HC Wainwright Downgrades Carisma Therapeutics to Neutral From Buy
MT Newswires
8 days ago
BTIG Downgrades Carisma Therapeutics to Neutral From Buy
PR Newswire
9 days ago
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
PR Newswire
21 days ago
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
MT Newswires
a month ago
Carisma Therapeutics Says Preclinical Data Support Potential of Engineered Macrophages to Treat Liver Fibrosis
PR Newswire
a month ago
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
PR Newswire
a month ago
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
PR Newswire
a month ago
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Compare CARM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CARM Carisma Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.